Concentra sees 2026 revenue between $2.325 bln and $2.375 bln
Company expects 2026 Adjusted EBITDA of $485 mln to $495 mln
Company projects 2026 free cash flow between $220 mln and $240 mln
Overview
US occupational health provider's Q2 revenue rose 10%, beating analyst expectations
Net income attributable to company grew 46.5% yr/yr in Q2
Company to appoint Matt DiCanio as CEO, Keith Newton to become executive chairman Nov. 1
Result Drivers
Organic growth and acquisitions - Co said higher net income was driven by organic growth and acquisitions, as well as timing variances in payments of current liabilities
Patient volume - Patient visits rose 2.6% yr/yr in Q2, supporting revenue growth
Revenue per visit - Revenue per visit increased 4.6% yr/yr in Q2
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
